資源描述：
《培美曲塞聯(lián)合順鉑一線治療晚期肺腺癌的近期療效與安全性觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、1324中國(guó)腫瘤臨床2013年第40卷第21期ChinJClinOncol2013，Vo1．40，No．21www．cjco．cn培美曲塞聯(lián)合順鉑一線治療晚期肺腺癌的近期療效與安全性觀察葉曉賢①袁瑛@沈虹②摘要目的：觀察培關(guān)曲塞聯(lián)合順鉑一線治療晚期肺腺癌的近期療效和安全性。方法：經(jīng)病理確診為肺腺癌的4l例初治(ⅢB～Ⅳ期)患者，采用培美曲塞聯(lián)合順鉑全身化療。每2個(gè)療程進(jìn)行療效及安全性評(píng)價(jià)。結(jié)果：41例患者均可評(píng)價(jià)療效，PR17例．sD20例．PD4例。總的客觀有效率(ORR)為41．5％，疾病控制率(DCR)90I3％。其中男性
2、患者有效率顯著高于女性患者(63．1％22．7％，P=0．009)。所有患者的中位PF$為11．0個(gè)月，中位0s為12．6個(gè)月。6例伴腦轉(zhuǎn)移患者經(jīng)化療同步全腦放療后的顱內(nèi)病灶得到較好控制，ORR為83．3％，DCR為100．0％。安全性方面，僅4．8％的患者出現(xiàn)了Ⅲ～Ⅳ度的中性粒細(xì)胞減少、惡心或嘔吐。結(jié)論：培美曲塞聯(lián)合順鉑一線治療晚期肺腺癌患者療效肯定，安全性良好。男性患者的有效率明顯高于女性患者。對(duì)伴有腦轉(zhuǎn)移的患者，化療同時(shí)進(jìn)行全腦放療，療效好且未額外增加不良反應(yīng)。關(guān)鍵詞肺腺癌培美曲塞順鉑近期療效安全性doi：10．3969／
3、j．issn．1000—8179．20130400Pemetrexedandplatinumasfirst-linechemotherapyforadvancedlungadenocarcinoma：anobservationofrecenttherapeuticeffectsandasafetyprofileXiaoxianYE，YingYUAN，HongSHENCorrespondenceto：YingYUAN；E—mail：yuanying1999@zju．edu．cnCancerChemoradiotherapyCent
4、er,NingboNo．1Hospital，Ningbo315000，China．DepartmentofMedicalOncology,SecondAfiliatedHospital，ZhejiangUniversityCollegeofMedicine，Hangzhou310009，China．Abstract0bjective：Therecenttherapeuticefectsandsafetyprofileofpemetrexedpluscisplatinasfirst—linechemotherapyinadvanc
5、edlungadenocarcinomawereevaluated．Methods：Atotalof41chemotherapy—naivelocallyadvancedormetastaticnon—smallcelllungcancerpatients，whowerediagnosedwithadenocarcinomabypathologicalexamination，wereincluded．Allpatientsreceived500mg／m2pemetrexedonday1．Atotaldoseof75mg／mcis
6、platinwasdividedintothreedailydosesadministeredover3d．Treat—mentswererepeatedeverythreeweeks．Thetherapeuticeficiencyandsafetyprofilewereevaluatedeverytwotreatmentcycles．Re-suits：All41patientswereeligiblefortheevaluationoftherapeuticeficiency．Seventeenpatientsshowedpa
7、rtialresponse20patients，showedstabledisease，andfourpatientsshoweddiseaseprogression．Theoverallresponserate(ORR)was41．5％andthediseasecon—trolrate(DCR)was90_3％．SubgroupanalysisshowedthattheORRinmaleswassignificantlyhigherthanthatinfemales(63．1％．22．7％，P=0．009)．Themedian
8、progression—freesurvivalofallpatientswas11．0months，whereasthemedianoverallsurvivalwas12．6months．Theintracraniallesionsofsixpatients
